Journal
JOURNAL OF VIROLOGICAL METHODS
Volume 169, Issue 2, Pages 259-268Publisher
ELSEVIER
DOI: 10.1016/j.jviromet.2010.07.015
Keywords
Rift Valley fever virus; Virus-like particles; Suspension cells; Vaccine production
Funding
- National Institute of Health [7U01AI066327]
- United States Medical Research & Material Command [W911NF-09-C-0072]
Ask authors/readers for more resources
Rift Valley fever virus (RVFV) is an arthropod-borne pathogen that often results in severe morbidity and mortality in both humans and livestock. As its geographic range continues to expand, it presents a real threat to naive populations around the world by accidental introduction (e.g., the result of increased travel) or intentional release (e.g., a bioterror event). While there is a clear need for a safe and efficacious vaccine against this emerging and re-emerging pathogen, no FDA-approved vaccine is currently available. This need was addressed by the establishment of novel mammalian and insect suspension cell line systems for the efficient production of RVF virus-like particle (VLP)-based vaccine candidates. A direct comparison of the production of RVF VLPs in these systems was performed. Optimization and characterization resulted in a production platform suitable for scale-up. Furthermore, RVF VLP-based vaccines were tested in a lethal challenge model and showed full protection, demonstrating that RVF VLPs present promising RVFV vaccine candidates. (C) 2010 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available